|1.||Zhou, Wenjun: 1 article (01/2012)|
|2.||Li, Zhimin: 1 article (01/2012)|
|3.||Lou, Linjie: 1 article (01/2012)|
|4.||Zhu, Lifang: 1 article (01/2012)|
|5.||Zhu, Lizhong: 1 article (01/2012)|
|1.||Chromosome Aberrations (Chromosome Abnormalities)
02/01/1999 - "In preclinical safety studies, DPHA was without effect in the Ames assay and at concentrations up to 3000 microg/plate in the presence or absence of metabolic activation, and in the in vitro micronucleus test with acute and 2-week repeated dose studies in Wistar rats at iv doses up to 15 mg/kg. In 4-week studies conducted in rats and dogs receiving fosphenytoin containing DPHA levels up to 1.1%, and in an in vitro structural chromosome aberration test with DPHA levels up to 2.0%, all findings were consistent with known effects of phenytoin (such as CNS signs and increased liver weight), and none were attributed to DPHA. "